BR112015002687A2 - regimes de tratamento - Google Patents
regimes de tratamento Download PDFInfo
- Publication number
- BR112015002687A2 BR112015002687A2 BR112015002687A BR112015002687A BR112015002687A2 BR 112015002687 A2 BR112015002687 A2 BR 112015002687A2 BR 112015002687 A BR112015002687 A BR 112015002687A BR 112015002687 A BR112015002687 A BR 112015002687A BR 112015002687 A2 BR112015002687 A2 BR 112015002687A2
- Authority
- BR
- Brazil
- Prior art keywords
- composition
- disorder
- sexual
- antagonist
- oxytocin
- Prior art date
Links
- 238000011269 treatment regimen Methods 0.000 title abstract 2
- 238000011282 treatment Methods 0.000 claims abstract description 91
- 230000035946 sexual desire Effects 0.000 claims abstract description 13
- 206010011953 Decreased activity Diseases 0.000 claims abstract 2
- 239000000203 mixture Substances 0.000 claims description 498
- 239000002400 serotonin 2A antagonist Substances 0.000 claims description 280
- 229940044601 receptor agonist Drugs 0.000 claims description 252
- 239000000018 receptor agonist Substances 0.000 claims description 252
- PHLBKPHSAVXXEF-UHFFFAOYSA-N trazodone Chemical compound ClC1=CC=CC(N2CCN(CCCN3C(N4C=CC=CC4=N3)=O)CC2)=C1 PHLBKPHSAVXXEF-UHFFFAOYSA-N 0.000 claims description 245
- 229960003991 trazodone Drugs 0.000 claims description 245
- 101800000989 Oxytocin Proteins 0.000 claims description 169
- XNOPRXBHLZRZKH-DSZYJQQASA-N oxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 claims description 169
- XNOPRXBHLZRZKH-UHFFFAOYSA-N Oxytocin Natural products N1C(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CC(C)C)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(C(C)CC)NC(=O)C1CC1=CC=C(O)C=C1 XNOPRXBHLZRZKH-UHFFFAOYSA-N 0.000 claims description 112
- 102100031951 Oxytocin-neurophysin 1 Human genes 0.000 claims description 112
- 229960001723 oxytocin Drugs 0.000 claims description 112
- SNPPWIUOZRMYNY-UHFFFAOYSA-N bupropion Chemical compound CC(C)(C)NC(C)C(=O)C1=CC=CC(Cl)=C1 SNPPWIUOZRMYNY-UHFFFAOYSA-N 0.000 claims description 109
- 229960001058 bupropion Drugs 0.000 claims description 109
- 208000012201 sexual and gender identity disease Diseases 0.000 claims description 95
- 208000015891 sexual disease Diseases 0.000 claims description 95
- 208000010877 cognitive disease Diseases 0.000 claims description 94
- 229940122381 Oxytocin receptor agonist Drugs 0.000 claims description 90
- 239000003937 drug carrier Substances 0.000 claims description 70
- 239000005557 antagonist Substances 0.000 claims description 64
- 239000000556 agonist Substances 0.000 claims description 52
- 239000003981 vehicle Substances 0.000 claims description 46
- 208000006262 Psychological Sexual Dysfunctions Diseases 0.000 claims description 44
- 206010024419 Libido decreased Diseases 0.000 claims description 42
- 208000017020 hypoactive sexual desire disease Diseases 0.000 claims description 42
- 230000000694 effects Effects 0.000 claims description 40
- 201000001880 Sexual dysfunction Diseases 0.000 claims description 39
- 206010012289 Dementia Diseases 0.000 claims description 38
- 231100000872 sexual dysfunction Toxicity 0.000 claims description 37
- 230000001568 sexual effect Effects 0.000 claims description 32
- 230000019771 cognition Effects 0.000 claims description 31
- 208000028698 Cognitive impairment Diseases 0.000 claims description 28
- 239000003112 inhibitor Substances 0.000 claims description 28
- 208000010228 Erectile Dysfunction Diseases 0.000 claims description 27
- 201000001881 impotence Diseases 0.000 claims description 26
- 208000019901 Anxiety disease Diseases 0.000 claims description 25
- 230000036506 anxiety Effects 0.000 claims description 24
- 208000024891 symptom Diseases 0.000 claims description 24
- 239000002767 noradrenalin uptake inhibitor Substances 0.000 claims description 20
- 229940127221 norepinephrine reuptake inhibitor Drugs 0.000 claims description 20
- 230000035936 sexual power Effects 0.000 claims description 20
- 239000003814 drug Substances 0.000 claims description 18
- 208000021663 Female sexual arousal disease Diseases 0.000 claims description 17
- 229940079593 drug Drugs 0.000 claims description 16
- 230000004064 dysfunction Effects 0.000 claims description 14
- 230000008133 cognitive development Effects 0.000 claims description 13
- 230000001771 impaired effect Effects 0.000 claims description 13
- 208000015421 male orgasm disease Diseases 0.000 claims description 12
- 201000000980 schizophrenia Diseases 0.000 claims description 10
- 208000024309 orgasm disease Diseases 0.000 claims description 8
- 230000001684 chronic effect Effects 0.000 claims description 7
- 208000027520 Somatoform disease Diseases 0.000 claims description 6
- 208000027753 pain disease Diseases 0.000 claims description 6
- 208000024827 Alzheimer disease Diseases 0.000 claims description 5
- 208000036640 Asperger disease Diseases 0.000 claims description 5
- 201000006062 Asperger syndrome Diseases 0.000 claims description 5
- 206010003805 Autism Diseases 0.000 claims description 5
- 208000020706 Autistic disease Diseases 0.000 claims description 5
- 208000020925 Bipolar disease Diseases 0.000 claims description 5
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 5
- 208000023105 Huntington disease Diseases 0.000 claims description 5
- 201000002832 Lewy body dementia Diseases 0.000 claims description 5
- 208000005314 Multi-Infarct Dementia Diseases 0.000 claims description 5
- 208000018737 Parkinson disease Diseases 0.000 claims description 5
- 201000004810 Vascular dementia Diseases 0.000 claims description 5
- 208000029028 brain injury Diseases 0.000 claims description 5
- 210000003169 central nervous system Anatomy 0.000 claims description 5
- 230000006999 cognitive decline Effects 0.000 claims description 5
- 230000007850 degeneration Effects 0.000 claims description 5
- 208000015181 infectious disease Diseases 0.000 claims description 5
- 208000020016 psychiatric disease Diseases 0.000 claims description 5
- 208000002193 Pain Diseases 0.000 claims description 3
- 230000006735 deficit Effects 0.000 claims description 3
- 102100022738 5-hydroxytryptamine receptor 1A Human genes 0.000 claims description 2
- 101710138638 5-hydroxytryptamine receptor 1A Proteins 0.000 claims description 2
- 102100028139 Oxytocin receptor Human genes 0.000 claims 28
- 238000004519 manufacturing process Methods 0.000 claims 19
- 230000015572 biosynthetic process Effects 0.000 claims 8
- 230000003340 mental effect Effects 0.000 claims 8
- 238000003786 synthesis reaction Methods 0.000 claims 8
- 206010067889 Dementia with Lewy bodies Diseases 0.000 claims 4
- 208000012239 Developmental disease Diseases 0.000 claims 4
- PPRRDFIXUUSXRA-UHFFFAOYSA-N flibanserin Chemical compound FC(F)(F)C1=CC=CC(N2CCN(CCN3C(NC4=CC=CC=C43)=O)CC2)=C1 PPRRDFIXUUSXRA-UHFFFAOYSA-N 0.000 claims 4
- 229960002053 flibanserin Drugs 0.000 claims 4
- 208000003906 hydrocephalus Diseases 0.000 claims 4
- 230000008520 organization Effects 0.000 claims 4
- 230000008447 perception Effects 0.000 claims 4
- 230000008521 reorganization Effects 0.000 claims 4
- 238000012800 visualization Methods 0.000 claims 4
- 238000013265 extended release Methods 0.000 claims 3
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 238000011200 topical administration Methods 0.000 claims 2
- 230000002035 prolonged effect Effects 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 84
- 150000001875 compounds Chemical class 0.000 abstract description 54
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 29
- 208000035475 disorder Diseases 0.000 abstract description 29
- 230000036299 sexual function Effects 0.000 abstract description 8
- 241000282414 Homo sapiens Species 0.000 abstract description 5
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000002484 serotonin 2C antagonist Substances 0.000 description 207
- 239000000674 adrenergic antagonist Substances 0.000 description 107
- 102000004279 Oxytocin receptors Human genes 0.000 description 105
- 108090000876 Oxytocin receptors Proteins 0.000 description 105
- 239000003795 chemical substances by application Substances 0.000 description 101
- -1 fiblanserin Chemical compound 0.000 description 98
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 96
- 102000035038 5-HT1 receptors Human genes 0.000 description 74
- 108091005478 5-HT1 receptors Proteins 0.000 description 74
- 229960003638 dopamine Drugs 0.000 description 73
- LJBBMCNHIUJBDU-UHFFFAOYSA-N talopram Chemical compound O1C(C)(C)C2=CC=CC=C2C1(CCCNC)C1=CC=CC=C1 LJBBMCNHIUJBDU-UHFFFAOYSA-N 0.000 description 72
- 229950007352 talopram Drugs 0.000 description 72
- 229940094659 Dopamine reuptake inhibitor Drugs 0.000 description 70
- 239000000221 dopamine uptake inhibitor Substances 0.000 description 70
- 229940044551 receptor antagonist Drugs 0.000 description 68
- 239000002464 receptor antagonist Substances 0.000 description 68
- 229960001785 mirtazapine Drugs 0.000 description 62
- RONZAEMNMFQXRA-UHFFFAOYSA-N mirtazapine Chemical compound C1C2=CC=CN=C2N2CCN(C)CC2C2=CC=CC=C21 RONZAEMNMFQXRA-UHFFFAOYSA-N 0.000 description 62
- 229960001800 nefazodone Drugs 0.000 description 62
- VRBKIVRKKCLPHA-UHFFFAOYSA-N nefazodone Chemical compound O=C1N(CCOC=2C=CC=CC=2)C(CC)=NN1CCCN(CC1)CCN1C1=CC=CC(Cl)=C1 VRBKIVRKKCLPHA-UHFFFAOYSA-N 0.000 description 62
- 102000049773 5-HT2A Serotonin Receptor Human genes 0.000 description 60
- 108010072564 5-HT2A Serotonin Receptor Proteins 0.000 description 60
- 229960001255 viloxazine Drugs 0.000 description 59
- YWPHCCPCQOJSGZ-LLVKDONJSA-N (2r)-2-[(2-ethoxyphenoxy)methyl]morpholine Chemical compound CCOC1=CC=CC=C1OC[C@@H]1OCCNC1 YWPHCCPCQOJSGZ-LLVKDONJSA-N 0.000 description 58
- ZPXSCAKFGYXMGA-UHFFFAOYSA-N Mazindol Chemical compound N12CCN=C2C2=CC=CC=C2C1(O)C1=CC=C(Cl)C=C1 ZPXSCAKFGYXMGA-UHFFFAOYSA-N 0.000 description 57
- 229960002430 atomoxetine Drugs 0.000 description 57
- VHGCDTVCOLNTBX-QGZVFWFLSA-N atomoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=CC=C1C VHGCDTVCOLNTBX-QGZVFWFLSA-N 0.000 description 57
- YFAIJBZEDDOCAN-UHFFFAOYSA-N daledalin Chemical compound C12=CC=CC=C2C(CCCNC)(C)CN1C1=CC=CC=C1 YFAIJBZEDDOCAN-UHFFFAOYSA-N 0.000 description 57
- 229950004863 lortalamine Drugs 0.000 description 57
- MJRPHRMGEKCADU-JVLSTEMRSA-N lortalamine Chemical compound C12=CC(Cl)=CC=C2O[C@]23CCN(C)C[C@@H]2[C@H]1CC(=O)N3 MJRPHRMGEKCADU-JVLSTEMRSA-N 0.000 description 57
- ITJNARMNRKSWTA-UHFFFAOYSA-N nisoxetine Chemical compound C=1C=CC=CC=1C(CCNC)OC1=CC=CC=C1OC ITJNARMNRKSWTA-UHFFFAOYSA-N 0.000 description 57
- 229950004211 nisoxetine Drugs 0.000 description 57
- 229960003770 reboxetine Drugs 0.000 description 57
- CBQGYUDMJHNJBX-RTBURBONSA-N reboxetine Chemical compound CCOC1=CC=CC=C1O[C@H](C=1C=CC=CC=1)[C@@H]1OCCNC1 CBQGYUDMJHNJBX-RTBURBONSA-N 0.000 description 57
- BRPOADLGOFPKKJ-UHFFFAOYSA-N tandamine Chemical compound C12=CC=CC=C2N(CC)C2=C1CCSC2(C)CCN(C)C BRPOADLGOFPKKJ-UHFFFAOYSA-N 0.000 description 57
- 229950006964 tandamine Drugs 0.000 description 57
- CPBHSHYQQLFAPW-ZWKOTPCHSA-N edivoxetine Chemical compound COC1=CC=C(F)C=C1C[C@](O)([C@H]1OCCNC1)C1CCOCC1 CPBHSHYQQLFAPW-ZWKOTPCHSA-N 0.000 description 56
- 229950003015 edivoxetine Drugs 0.000 description 56
- CBQGYUDMJHNJBX-OALUTQOASA-N (2S)-2-[(S)-(2-ethoxyphenoxy)-phenylmethyl]morpholine Chemical compound CCOC1=CC=CC=C1O[C@@H](C=1C=CC=CC=1)[C@H]1OCCNC1 CBQGYUDMJHNJBX-OALUTQOASA-N 0.000 description 55
- 229950008247 esreboxetine Drugs 0.000 description 55
- 229960000299 mazindol Drugs 0.000 description 54
- FKHYYOUFMJBLAF-UHFFFAOYSA-N 3-(3,3-dimethyl-1-phenyl-2-benzothiophen-1-yl)-n-methylpropan-1-amine Chemical compound S1C(C)(C)C2=CC=CC=C2C1(CCCNC)C1=CC=CC=C1 FKHYYOUFMJBLAF-UHFFFAOYSA-N 0.000 description 53
- 229950002139 talsupram Drugs 0.000 description 53
- NSTRIRCPWQHTIA-DTRKZRJBSA-N carbetocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSCCCC(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(OC)C=C1 NSTRIRCPWQHTIA-DTRKZRJBSA-N 0.000 description 52
- 108700021293 carbetocin Proteins 0.000 description 52
- 229960001118 carbetocin Drugs 0.000 description 52
- XTTZERNUQAFMOF-QMMMGPOBSA-N lorcaserin Chemical compound C[C@H]1CNCCC2=CC=C(Cl)C=C12 XTTZERNUQAFMOF-QMMMGPOBSA-N 0.000 description 51
- 229960005060 lorcaserin Drugs 0.000 description 51
- VSWBSWWIRNCQIJ-GJZGRUSLSA-N (R,R)-asenapine Chemical compound O1C2=CC=CC=C2[C@@H]2CN(C)C[C@H]2C2=CC(Cl)=CC=C21 VSWBSWWIRNCQIJ-GJZGRUSLSA-N 0.000 description 49
- VHFVKMTVMIZMIK-UHFFFAOYSA-N 1-(3-chlorophenyl)piperazine Chemical compound ClC1=CC=CC(N2CCNCC2)=C1 VHFVKMTVMIZMIK-UHFFFAOYSA-N 0.000 description 49
- 229960005245 asenapine Drugs 0.000 description 49
- 229960004170 clozapine Drugs 0.000 description 49
- QZUDBNBUXVUHMW-UHFFFAOYSA-N clozapine Chemical compound C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 description 49
- KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 description 49
- 229960005017 olanzapine Drugs 0.000 description 49
- URKOMYMAXPYINW-UHFFFAOYSA-N quetiapine Chemical compound C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12 URKOMYMAXPYINW-UHFFFAOYSA-N 0.000 description 49
- 229960004431 quetiapine Drugs 0.000 description 49
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 48
- 244000194101 Ginkgo biloba Species 0.000 description 48
- 235000008100 Ginkgo biloba Nutrition 0.000 description 48
- FPCCSQOGAWCVBH-UHFFFAOYSA-N ketanserin Chemical compound C1=CC(F)=CC=C1C(=O)C1CCN(CCN2C(C3=CC=CC=C3NC2=O)=O)CC1 FPCCSQOGAWCVBH-UHFFFAOYSA-N 0.000 description 48
- 229960005417 ketanserin Drugs 0.000 description 48
- 229960002748 norepinephrine Drugs 0.000 description 48
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 48
- RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 description 48
- 229960001534 risperidone Drugs 0.000 description 48
- JUQLTPCYUFPYKE-UHFFFAOYSA-N ritanserin Chemical compound CC=1N=C2SC=CN2C(=O)C=1CCN(CC1)CCC1=C(C=1C=CC(F)=CC=1)C1=CC=C(F)C=C1 JUQLTPCYUFPYKE-UHFFFAOYSA-N 0.000 description 48
- 229950009626 ritanserin Drugs 0.000 description 48
- QLOOWOVVZLBYHU-VIFPVBQESA-N (2s)-1-(7-ethylfuro[2,3-g]indazol-1-yl)propan-2-amine Chemical compound O1C(CC)=CC2=C1C=CC1=C2N(C[C@H](C)N)N=C1 QLOOWOVVZLBYHU-VIFPVBQESA-N 0.000 description 47
- LKKWNBWRPDKMIB-UHFFFAOYSA-N 3-chloro-1-phenylpiperazine Chemical compound C1CNC(Cl)CN1C1=CC=CC=C1 LKKWNBWRPDKMIB-UHFFFAOYSA-N 0.000 description 47
- CEUORZQYGODEFX-UHFFFAOYSA-N Aripirazole Chemical compound ClC1=CC=CC(N2CCN(CCCCOC=3C=C4NC(=O)CCC4=CC=3)CC2)=C1Cl CEUORZQYGODEFX-UHFFFAOYSA-N 0.000 description 47
- 229960004372 aripiprazole Drugs 0.000 description 47
- 210000004556 brain Anatomy 0.000 description 47
- QSLMDECMDJKHMQ-GSXCWMCISA-N maprotiline Chemical compound C12=CC=CC=C2[C@@]2(CCCNC)C3=CC=CC=C3[C@@H]1CC2 QSLMDECMDJKHMQ-GSXCWMCISA-N 0.000 description 46
- 229960004090 maprotiline Drugs 0.000 description 46
- JJCFRYNCJDLXIK-UHFFFAOYSA-N cyproheptadine Chemical compound C1CN(C)CCC1=C1C2=CC=CC=C2C=CC2=CC=CC=C21 JJCFRYNCJDLXIK-UHFFFAOYSA-N 0.000 description 45
- 229960001140 cyproheptadine Drugs 0.000 description 45
- 244000141009 Hypericum perforatum Species 0.000 description 42
- 235000017309 Hypericum perforatum Nutrition 0.000 description 42
- 239000002485 serotonin 2C agonist Substances 0.000 description 38
- RCOBKSKAZMVBHT-TVQRCGJNSA-N radafaxine Chemical compound C[C@@H]1NC(C)(C)CO[C@@]1(O)C1=CC=CC(Cl)=C1 RCOBKSKAZMVBHT-TVQRCGJNSA-N 0.000 description 36
- 229950010561 radafaxine Drugs 0.000 description 36
- KWTWDQCKEHXFFR-SMDDNHRTSA-N tapentadol Chemical compound CN(C)C[C@H](C)[C@@H](CC)C1=CC=CC(O)=C1 KWTWDQCKEHXFFR-SMDDNHRTSA-N 0.000 description 36
- 229960005126 tapentadol Drugs 0.000 description 36
- OILWWIVKIDXCIB-UHFFFAOYSA-N teniloxazine Chemical compound C1NCCOC1COC1=CC=CC=C1CC1=CC=CS1 OILWWIVKIDXCIB-UHFFFAOYSA-N 0.000 description 35
- 229950003014 teniloxazine Drugs 0.000 description 35
- HXTGXYRHXAGCFP-OAQYLSRUSA-N (r)-(2,3-dimethoxyphenyl)-[1-[2-(4-fluorophenyl)ethyl]piperidin-4-yl]methanol Chemical compound COC1=CC=CC([C@H](O)C2CCN(CCC=3C=CC(F)=CC=3)CC2)=C1OC HXTGXYRHXAGCFP-OAQYLSRUSA-N 0.000 description 30
- 239000003723 serotonin 1A agonist Substances 0.000 description 26
- 239000002399 serotonin 2A agonist Substances 0.000 description 11
- 102100024959 5-hydroxytryptamine receptor 2C Human genes 0.000 description 10
- 101710138093 5-hydroxytryptamine receptor 2C Proteins 0.000 description 10
- 206010012601 diabetes mellitus Diseases 0.000 description 10
- 208000002551 irritable bowel syndrome Diseases 0.000 description 10
- 206010028980 Neoplasm Diseases 0.000 description 9
- 230000037007 arousal Effects 0.000 description 9
- 201000011510 cancer Diseases 0.000 description 9
- 230000009429 distress Effects 0.000 description 9
- 102000056834 5-HT2 Serotonin Receptors Human genes 0.000 description 8
- 108091005479 5-HT2 receptors Proteins 0.000 description 8
- 206010057672 Male sexual dysfunction Diseases 0.000 description 8
- NPTIPEQJIDTVKR-STQMWFEESA-N vabicaserin Chemical compound C1CNCC2=CC=CC3=C2N1C[C@@H]1CCC[C@@H]13 NPTIPEQJIDTVKR-STQMWFEESA-N 0.000 description 8
- 229950009968 vabicaserin Drugs 0.000 description 8
- 206010054089 Depressive symptom Diseases 0.000 description 6
- 208000019022 Mood disease Diseases 0.000 description 6
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 6
- OZGPVYJHWWPEFT-RGNHYFCHSA-N manifaxine Chemical compound C[C@@H]1N[C@H](C)CO[C@@]1(O)C1=CC(F)=CC(F)=C1 OZGPVYJHWWPEFT-RGNHYFCHSA-N 0.000 description 6
- 229950006048 manifaxine Drugs 0.000 description 6
- 230000003924 mental process Effects 0.000 description 6
- 230000036651 mood Effects 0.000 description 6
- 206010036596 premature ejaculation Diseases 0.000 description 6
- 238000004448 titration Methods 0.000 description 6
- 206010057671 Female sexual dysfunction Diseases 0.000 description 5
- 102000006902 5-HT2C Serotonin Receptor Human genes 0.000 description 4
- 108010072553 5-HT2C Serotonin Receptor Proteins 0.000 description 4
- 206010010144 Completed suicide Diseases 0.000 description 4
- 208000004483 Dyspareunia Diseases 0.000 description 4
- 230000001154 acute effect Effects 0.000 description 4
- 230000003466 anti-cipated effect Effects 0.000 description 4
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 4
- 238000011458 pharmacological treatment Methods 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 230000001800 adrenalinergic effect Effects 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 239000002160 alpha blocker Substances 0.000 description 3
- 230000006399 behavior Effects 0.000 description 3
- HLOCJJORRHQDKS-UHFFFAOYSA-N cp-39,332 Chemical compound C12=CC=CC=C2CC(NC)CC1C1=CC=CC=C1 HLOCJJORRHQDKS-UHFFFAOYSA-N 0.000 description 3
- 230000003111 delayed effect Effects 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 208000024714 major depressive disease Diseases 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 239000000932 sedative agent Substances 0.000 description 3
- 230000001624 sedative effect Effects 0.000 description 3
- 229960003604 testosterone Drugs 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 206010063659 Aversion Diseases 0.000 description 2
- 208000020401 Depressive disease Diseases 0.000 description 2
- 208000028017 Psychotic disease Diseases 0.000 description 2
- 239000000935 antidepressant agent Substances 0.000 description 2
- 229940005513 antidepressants Drugs 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- VKQDZNZTPGLGFD-UHFFFAOYSA-N ciclazindol Chemical compound C12=NCCCN2C2=CC=CC=C2C1(O)C1=CC=CC(Cl)=C1 VKQDZNZTPGLGFD-UHFFFAOYSA-N 0.000 description 2
- 229950009468 ciclazindol Drugs 0.000 description 2
- 230000001856 erectile effect Effects 0.000 description 2
- 230000005713 exacerbation Effects 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 238000001050 pharmacotherapy Methods 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- 229940068196 placebo Drugs 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 208000022610 schizoaffective disease Diseases 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- YWPHCCPCQOJSGZ-UHFFFAOYSA-N 2-[(2-ethoxyphenoxy)methyl]morpholine Chemical compound CCOC1=CC=CC=C1OCC1OCCNC1 YWPHCCPCQOJSGZ-UHFFFAOYSA-N 0.000 description 1
- 240000006108 Allium ampeloprasum Species 0.000 description 1
- 206010002942 Apathy Diseases 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 206010011971 Decreased interest Diseases 0.000 description 1
- 235000011201 Ginkgo Nutrition 0.000 description 1
- 208000009829 Lewy Body Disease Diseases 0.000 description 1
- 206010024870 Loss of libido Diseases 0.000 description 1
- QSLMDECMDJKHMQ-UHFFFAOYSA-N Maprotiline Chemical compound C12=CC=CC=C2C2(CCCNC)C3=CC=CC=C3C1CC2 QSLMDECMDJKHMQ-UHFFFAOYSA-N 0.000 description 1
- 208000012202 Pervasive developmental disease Diseases 0.000 description 1
- 206010037180 Psychiatric symptoms Diseases 0.000 description 1
- 206010041250 Social phobia Diseases 0.000 description 1
- 210000004727 amygdala Anatomy 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000000049 anti-anxiety effect Effects 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 208000029560 autism spectrum disease Diseases 0.000 description 1
- 150000001538 azepines Chemical class 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000003930 cognitive ability Effects 0.000 description 1
- 230000007370 cognitive improvement Effects 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 239000013256 coordination polymer Substances 0.000 description 1
- 238000009223 counseling Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000013367 dietary fats Nutrition 0.000 description 1
- 230000009986 erectile function Effects 0.000 description 1
- 239000010520 ghee Substances 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000003521 serotonin 5-HT1 receptor agonist Substances 0.000 description 1
- 239000003478 serotonin 5-HT2 receptor agonist Substances 0.000 description 1
- 239000003215 serotonin 5-HT2 receptor antagonist Substances 0.000 description 1
- 239000000952 serotonin receptor agonist Substances 0.000 description 1
- 230000009329 sexual behaviour Effects 0.000 description 1
- 230000000192 social effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000000859 sublimation Methods 0.000 description 1
- 230000008022 sublimation Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/095—Oxytocins; Vasopressins; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Zoology (AREA)
- Gynecology & Obstetrics (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Pregnancy & Childbirth (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261679999P | 2012-08-06 | 2012-08-06 | |
| PCT/US2013/053843 WO2014025814A1 (en) | 2012-08-06 | 2013-08-06 | Treatment regimens |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112015002687A2 true BR112015002687A2 (pt) | 2019-12-17 |
Family
ID=50068530
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112015002687A BR112015002687A2 (pt) | 2012-08-06 | 2013-08-06 | regimes de tratamento |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US9517254B2 (https=) |
| EP (1) | EP2879680A4 (https=) |
| JP (2) | JP2015524474A (https=) |
| KR (4) | KR20230136142A (https=) |
| CN (2) | CN104884060A (https=) |
| AU (2) | AU2013299725A1 (https=) |
| BR (1) | BR112015002687A2 (https=) |
| CA (1) | CA2881388A1 (https=) |
| EA (1) | EA201590349A1 (https=) |
| HK (2) | HK1211239A1 (https=) |
| IL (1) | IL237150B (https=) |
| MX (1) | MX2015001695A (https=) |
| SG (3) | SG10201709967YA (https=) |
| WO (1) | WO2014025814A1 (https=) |
| ZA (1) | ZA201501562B (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UY36742A (es) * | 2016-06-17 | 2016-12-30 | S1 Biopharma Inc | Métodos para el tratamiento de mujeres con trastorno del deseo sexual hipoactivo (hsdd) con tratamiento de combinación de bupropión y trazodona |
| WO2023168023A1 (en) | 2022-03-04 | 2023-09-07 | Reset Pharmaceuticals, Inc. | Co-crystals or salts comprising psilocin |
| WO2025042884A2 (en) * | 2023-08-21 | 2025-02-27 | Kuleon Llc | Serotonin receptor modulators for the treatment of addictions and overdoses |
| US11977085B1 (en) | 2023-09-05 | 2024-05-07 | Elan Ehrlich | Date rape drug detection device and method of using same |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4687771A (en) * | 1985-11-01 | 1987-08-18 | Bristol-Myers Company | Method for treatment of male impotence |
| DE4321965A1 (de) * | 1993-07-01 | 1995-01-12 | Cytech Biomedical Inc | Oxytocin-haltige Zusammensetzung sowie die Verwendung derselben als Mittel, insbesondere Nasenspray zur Behandlung sexueller Dysfunktionen |
| US6337328B1 (en) | 1999-03-01 | 2002-01-08 | Sepracor, Inc. | Bupropion metabolites and methods of use |
| JP2002322085A (ja) * | 2001-04-26 | 2002-11-08 | Kazuhito Tomizawa | 知的機能障害治療剤 |
| UA78974C2 (en) * | 2001-10-20 | 2007-05-10 | Boehringer Ingelheim Pharma | Use of flibanserin for treating disorders of sexual desire |
| ES2353690T3 (es) | 2002-10-03 | 2011-03-04 | Neuropharmacology Services, Llc | Oxitocina para su uso en el tratamiento del autismo y del trastorno de asperger. |
| WO2004078147A2 (en) * | 2003-03-05 | 2004-09-16 | Pr Pharmaceuticals | Oxytocin controlled release formulations and methods of using same |
| AU2005235422B2 (en) | 2004-04-22 | 2011-08-11 | Boehringer Ingelheim International Gmbh | New pharmaceutical compositions for the treatment of sexual disorders II |
| CN1946404A (zh) * | 2004-04-22 | 2007-04-11 | 贝林格尔·英格海姆国际有限公司 | 用于治疗性功能疾病ⅱ的新颖药物组合物 |
| US20060004076A1 (en) | 2004-06-30 | 2006-01-05 | Inflabloc Pharmaceuticals, Inc. | Co-administration of dehydroepiandrosterone (DHEA) congener with pharmaceutically active agents for treating inflammation |
| EP1827450A4 (en) | 2004-11-17 | 2009-04-22 | Cypress Bioscience Inc | METHOD FOR REDUCING THE SIDE EFFECTS OF TREATMENT WITH MIRTAZAPINE |
| WO2006096435A1 (en) * | 2005-03-04 | 2006-09-14 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions for the treatment and/or prevention of depression |
| US9023793B2 (en) * | 2006-09-29 | 2015-05-05 | Retrophin, Inc. | Intranasal carbetocin formulations and methods for the treatment of autism |
| MX2009004798A (es) * | 2006-10-31 | 2009-08-12 | Janssen Pharmaceutica Nv | Tratamiento de los trastornos generalizados del desarrollo. |
| WO2008075162A2 (en) * | 2006-12-15 | 2008-06-26 | Pfizer Limited | Selective mu opioid receptor antagonists for the treatment of female sexual dysfunction |
| WO2009016488A2 (en) * | 2007-08-02 | 2009-02-05 | Compugen, Ltd. | Compositions comprising tetracyclic antidepressants for treatment of cancer and related methods |
| AU2009282822A1 (en) * | 2008-08-21 | 2010-02-25 | Richter Gedeon Nyrt. | Methods for treating CNS disorders |
| EP2389187B1 (en) * | 2009-01-20 | 2016-11-16 | Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center | Sorbic and benzoic acid and derivatives thereof enhance the activity of a neuropharmaceutical |
| WO2011140608A1 (en) | 2010-05-14 | 2011-11-17 | Keating Charlotte L | Neuropsychopharmacological treatment regimes for treating psychological disorders |
| EP2571360A4 (en) * | 2010-05-19 | 2013-07-31 | Univ North Carolina | METHOD AND FORMULATIONS FOR OXYTOCIN TREATMENT OF DRUG ABUSE AND PSYCHIATRIC AND OTHER DISORDERS |
| WO2012016229A2 (en) * | 2010-07-30 | 2012-02-02 | The Regents Of The University Of California | Oxytocin treatment to improve memory and modify blood glucose |
| SG10201609297VA (en) * | 2011-04-04 | 2016-12-29 | S1 Biopharma Inc | Treatment regimens |
-
2013
- 2013-08-06 HK HK15112183.5A patent/HK1211239A1/xx unknown
- 2013-08-06 HK HK16102368.2A patent/HK1214505A1/zh unknown
- 2013-08-06 BR BR112015002687A patent/BR112015002687A2/pt not_active IP Right Cessation
- 2013-08-06 CA CA2881388A patent/CA2881388A1/en not_active Abandoned
- 2013-08-06 CN CN201380052215.1A patent/CN104884060A/zh active Pending
- 2013-08-06 WO PCT/US2013/053843 patent/WO2014025814A1/en not_active Ceased
- 2013-08-06 US US14/420,112 patent/US9517254B2/en active Active
- 2013-08-06 KR KR1020237027646A patent/KR20230136142A/ko not_active Ceased
- 2013-08-06 EP EP13827390.9A patent/EP2879680A4/en not_active Withdrawn
- 2013-08-06 EA EA201590349A patent/EA201590349A1/ru unknown
- 2013-08-06 AU AU2013299725A patent/AU2013299725A1/en not_active Abandoned
- 2013-08-06 KR KR1020157006024A patent/KR20150063039A/ko not_active Ceased
- 2013-08-06 KR KR1020207031031A patent/KR20200128437A/ko not_active Ceased
- 2013-08-06 SG SG10201709967YA patent/SG10201709967YA/en unknown
- 2013-08-06 SG SG11201500919PA patent/SG11201500919PA/en unknown
- 2013-08-06 CN CN201710010422.0A patent/CN106924259A/zh active Pending
- 2013-08-06 SG SG10201908587P patent/SG10201908587PA/en unknown
- 2013-08-06 MX MX2015001695A patent/MX2015001695A/es unknown
- 2013-08-06 JP JP2015526649A patent/JP2015524474A/ja not_active Ceased
- 2013-08-06 KR KR1020257008033A patent/KR20250041078A/ko active Pending
-
2015
- 2015-02-08 IL IL237150A patent/IL237150B/en active IP Right Grant
- 2015-03-06 ZA ZA2015/01562A patent/ZA201501562B/en unknown
-
2018
- 2018-05-30 JP JP2018103554A patent/JP2018150357A/ja active Pending
- 2018-07-11 AU AU2018205121A patent/AU2018205121A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| KR20200128437A (ko) | 2020-11-12 |
| AU2018205121A1 (en) | 2018-07-26 |
| CN106924259A (zh) | 2017-07-07 |
| AU2013299725A1 (en) | 2015-03-26 |
| HK1211239A1 (en) | 2016-05-20 |
| SG10201908587PA (en) | 2019-10-30 |
| KR20230136142A (ko) | 2023-09-26 |
| CA2881388A1 (en) | 2014-02-13 |
| ZA201501562B (en) | 2017-11-29 |
| EP2879680A4 (en) | 2016-06-01 |
| US9517254B2 (en) | 2016-12-13 |
| KR20250041078A (ko) | 2025-03-25 |
| KR20150063039A (ko) | 2015-06-08 |
| IL237150B (en) | 2018-07-31 |
| US20150150946A1 (en) | 2015-06-04 |
| SG10201709967YA (en) | 2018-01-30 |
| WO2014025814A1 (en) | 2014-02-13 |
| MX2015001695A (es) | 2015-09-28 |
| IL237150A0 (en) | 2015-04-30 |
| HK1214505A1 (zh) | 2016-07-29 |
| EP2879680A1 (en) | 2015-06-10 |
| CN104884060A (zh) | 2015-09-02 |
| SG11201500919PA (en) | 2015-04-29 |
| JP2018150357A (ja) | 2018-09-27 |
| JP2015524474A (ja) | 2015-08-24 |
| EA201590349A1 (ru) | 2015-07-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2018264030A1 (en) | Treatment regimens | |
| AU2018205121A1 (en) | Treatment regimens | |
| CA2933921A1 (en) | Methods of treating women for hypoactive sexual desire disorder (hsdd) with bupropion and trazodone combination treatment | |
| WO2025245102A2 (en) | Methods and compositions for treating sexual disorder, weight loss, weight maintenance, well-being, and self-esteem | |
| HK1240825A1 (en) | Treatment regimens | |
| US20130267533A1 (en) | 5ht1a agonists for treatment of high cholesterol |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B06I | Publication of requirement cancelled [chapter 6.9 patent gazette] |
Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA. |
|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 5A ANUIDADE. |
|
| B08G | Application fees: restoration [chapter 8.7 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 8A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2631 DE 08-06-2021 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |
|
| B350 | Update of information on the portal [chapter 15.35 patent gazette] |